Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Insider Sells $93,007.67 in Stock

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) insider Ingrid Delaet sold 623 shares of the company’s stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $149.29, for a total value of $93,007.67. Following the transaction, the insider now directly owns 3,442 shares of the company’s stock, valued at approximately $513,856.18. This trade represents a 15.33 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Ingrid Delaet also recently made the following trade(s):

• On Tuesday, December 31st, Ingrid Delaet sold 272 shares of Neurocrine Biosciences stock. The shares were sold at an average price of $138.10, for a total value of $37,563.20.
• On Tuesday, December 17th, Ingrid Delaet sold 1,091 shares of Neurocrine Biosciences stock. The shares were sold at an average price of $135.00, for a total value of $147,285.00.

Neurocrine Biosciences Stock Up 1.5 %

Shares of NASDAQ:NBIX traded up $2.32 during trading on Tuesday, hitting $152.42. The stock had a trading volume of 814,308 shares, compared to its average volume of 950,096. Neurocrine Biosciences, Inc. has a 12 month low of $110.95 and a 12 month high of $157.98. The company has a market capitalization of $15.43 billion, a PE ratio of 40.86 and a beta of 0.33. The firm’s fifty day moving average is $137.92 and its 200 day moving average is $131.51.

Institutional Trading of Neurocrine Biosciences

Several hedge funds and other institutional investors have recently made changes to their positions in NBIX. Golden State Wealth Management LLC purchased a new stake in shares of Neurocrine Biosciences in the 4th quarter worth approximately $25,000. Brooklyn Investment Group boosted its stake in Neurocrine Biosciences by 99.1% during the 4th quarter. Brooklyn Investment Group now owns 231 shares of the company’s stock valued at $32,000 after purchasing an additional 115 shares during the last quarter. Blue Trust Inc. boosted its stake in Neurocrine Biosciences by 171.9% during the 3rd quarter. Blue Trust Inc. now owns 348 shares of the company’s stock valued at $40,000 after purchasing an additional 220 shares during the last quarter. R Squared Ltd purchased a new stake in Neurocrine Biosciences during the 4th quarter valued at $61,000. Finally, UMB Bank n.a. boosted its stake in Neurocrine Biosciences by 211.6% during the 4th quarter. UMB Bank n.a. now owns 455 shares of the company’s stock valued at $62,000 after purchasing an additional 309 shares during the last quarter. Hedge funds and other institutional investors own 92.59% of the company’s stock.

Analyst Ratings Changes

NBIX has been the topic of several analyst reports. Needham & Company LLC reissued a “hold” rating on shares of Neurocrine Biosciences in a report on Friday, December 20th. BMO Capital Markets reduced their price objective on Neurocrine Biosciences from $128.00 to $114.00 and set a “market perform” rating on the stock in a research note on Thursday, October 17th. Raymond James reaffirmed an “outperform” rating and issued a $155.00 price objective on shares of Neurocrine Biosciences in a research note on Thursday, October 10th. HC Wainwright reaffirmed a “buy” rating and issued a $190.00 price objective on shares of Neurocrine Biosciences in a research note on Monday, December 16th. Finally, William Blair reaffirmed an “outperform” rating on shares of Neurocrine Biosciences in a research note on Monday, December 16th. Five research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $166.85.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.